For more than two decades STARmed has delivered stable, clinically validated radio-frequency ablation solutions. We developed the world’s first thyroid-specific RF electrode, redefining a treatment landscape once dominated by surgery. ​ ​Today that electrode features in over 70 percent of global thyroid RFA studies, underlining physician confidence in our technology. Our portfolio now covers precision devices for uterine fibroids, hepatocellular carcinoma, benign prostatic hyperplasia, pancreas, biliary tract and other solid tumours. ​ The sharp, triangular-tip electrode enables safe, accurate puncture, while proprietary composite materials optimise energy delivery and heat diffusion. Continuous R&D focuses on design refinements that raise procedural safety and economic efficiency.​ ​ Direct subsidiaries in the United States and China, coupled with collaborations with key opinion leaders worldwide, ensure that products match real-world clinical needs. Acting as a solutions partner rather than a simple manufacturer, we have improved the lives of more than one million patients in over 70 countries and sustained compound annual growth above 35 percent.​